Loading…
The data demonstrated >90% Tumor Growth Inhibition and Significant Survival Benefit.
Propanc Biopharma, Inc. announced Propanc Biopharma announced new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma.
The announcement cited >90% Tumor Growth Inhibition, and Significant Survival Benefit.
Propanc Biopharma, Inc. has a free float of 1,250,074 shares and 3,503,116 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.